370 related articles for article (PubMed ID: 22023702)
21. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study.
Strober BE; Poulin Y; Kerdel FA; Langley RG; Gu Y; Gupta SR; Okun MM; Papp KA
J Am Acad Dermatol; 2011 Apr; 64(4):671-81. PubMed ID: 21414495
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of Adalimumab in the treatment of moderate to severe palmo-plantar psoriasis: an open label study.
Richetta AG; Mattozzi C; Giancristoforo S; D'Epiro S; Cantisani C; Macaluso L; Salvi M; Calvieri S
Clin Ter; 2012; 163(2):e61-6. PubMed ID: 22555836
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept.
Bissonnette R; Bolduc C; Poulin Y; Guenther L; Lynde CW; Maari C
J Am Acad Dermatol; 2010 Aug; 63(2):228-34. PubMed ID: 20494479
[TBL] [Abstract][Full Text] [Related]
25. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients.
van Lümig PP; van de Kerkhof PC; Boezeman JB; Driessen RJ; de Jong EM
J Eur Acad Dermatol Venereol; 2013 May; 27(5):593-600. PubMed ID: 22416818
[TBL] [Abstract][Full Text] [Related]
26. An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment.
Taniguchi T; Noda S; Takahashi N; Yoshimura H; Mizuno K; Adachi M
J Eur Acad Dermatol Venereol; 2013 Nov; 27(11):1444-7. PubMed ID: 22702802
[TBL] [Abstract][Full Text] [Related]
27. Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice.
Shear NH; Hartmann M; Toledo-Bahena M; Katsambas A; Connors L; Chang Q; Yao R; Nograles K; Popmihajlov Z;
Br J Dermatol; 2014 Sep; 171(3):631-41. PubMed ID: 24673357
[TBL] [Abstract][Full Text] [Related]
28. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
Papp K; Crowley J; Ortonne JP; Leu J; Okun M; Gupta SR; Gu Y; Langley RG
Br J Dermatol; 2011 Feb; 164(2):434-41. PubMed ID: 21083543
[TBL] [Abstract][Full Text] [Related]
29. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
30. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
33. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
Gordon KB; Langley RG; Leonardi C; Toth D; Menter MA; Kang S; Heffernan M; Miller B; Hamlin R; Lim L; Zhong J; Hoffman R; Okun MM
J Am Acad Dermatol; 2006 Oct; 55(4):598-606. PubMed ID: 17010738
[TBL] [Abstract][Full Text] [Related]
34. Bimekizumab versus Adalimumab in Plaque Psoriasis.
Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
Kimball AB; Bensimon AG; Guerin A; Yu AP; Wu EQ; Okun MM; Bao Y; Gupta SR; Mulani PM
Am J Clin Dermatol; 2011 Feb; 12(1):51-62. PubMed ID: 21110526
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
37. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
Shikiar R; Heffernan M; Langley RG; Willian MK; Okun MM; Revicki DA
J Dermatolog Treat; 2007; 18(1):25-31. PubMed ID: 17365264
[TBL] [Abstract][Full Text] [Related]
38. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Mease PJ; Gladman DD; Ritchlin CT; Ruderman EM; Steinfeld SD; Choy EH; Sharp JT; Ory PA; Perdok RJ; Weinberg MA;
Arthritis Rheum; 2005 Oct; 52(10):3279-89. PubMed ID: 16200601
[TBL] [Abstract][Full Text] [Related]
39. Intermittent etanercept therapy in pediatric patients with psoriasis.
Siegfried EC; Eichenfield LF; Paller AS; Pariser D; Creamer K; Kricorian G
J Am Acad Dermatol; 2010 Nov; 63(5):769-74. PubMed ID: 20833444
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study.
Cai L; Gu J; Zheng J; Zheng M; Wang G; Xi LY; Hao F; Liu XM; Sun QN; Wang Y; Lai W; Fang H; Tu YT; Sun Q; Chen J; Gao XH; Gu Y; Teixeira HD; Zhang JZ; Okun MM
J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):89-95. PubMed ID: 27504914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
